TScan Therapeutics (TCRX) Asset Utilization Ratio (2021 - 2026)
TScan Therapeutics (TCRX) posted quarterly Asset Utilization Ratio of 0.04 for Q1 2026, up 237.63% year-over-year from 0.01 in Q1 2025, and up 0.86% quarter-over-quarter from 0.04 in Q4 2025.
TScan Therapeutics (TCRX) Asset Utilization Ratio (2021 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Asset Utilization Ratio for 6 consecutive years, with 0.04 the latest figure, recorded in Q1 2026.
- In Q1 2026, Asset Utilization Ratio rose 237.63% year-over-year to 0.04; the TTM figure through Mar 2026 stood at 0.04 (up 237.63% YoY), while the FY2025 annual figure was 0.03, up 293.16% from the prior year.
- Asset Utilization Ratio improved to 0.04 in Q1 2026 per TCRX's latest filing, from 0.04 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.09 in Q1 2023 and bottomed at 0.01 in Q4 2024.
- Historically, Asset Utilization Ratio has averaged 0.05 across 5 years, with a median of 0.05 in 2023.
- Annual changes were most pronounced in 2024 — Asset Utilization Ratio tumbled 88.99% — and 2025, when it soared 437.01%.
- TScan Therapeutics' Asset Utilization Ratio stood at 0.07 in 2022, then dropped by 4.19% to 0.07 in 2023, then sank by 88.99% to 0.01 in 2024, then surged by 437.01% to 0.04 in 2025, then gained by 0.86% to 0.04 in 2026.
- Business Quant data shows TCRX's Asset Utilization Ratio at 0.04 in Q1 2026, 0.04 in Q4 2025, and 0.03 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 0.90 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 0.54 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 0.13 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 0.13 |
| 10 | TScan Therapeutics | 101.63 Mn | 101.63 Mn | - | 0.04 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.04 |
| Mar 31, 2026 | 0.04 |
| Dec 31, 2025 | 0.04 |
| Sep 30, 2025 | 0.03 |
| Jun 30, 2025 | 0.02 |
| Mar 31, 2025 | 0.01 |
| Dec 31, 2024 | 0.01 |
| Sep 30, 2024 | 0.03 |
| Jun 30, 2024 | 0.04 |
| Mar 31, 2024 | 0.06 |
| Dec 31, 2023 | 0.07 |
| Sep 30, 2023 | 0.05 |
| Jun 30, 2023 | 0.06 |
| Mar 31, 2023 | 0.09 |
| Dec 31, 2022 | 0.07 |
| Sep 30, 2022 | 0.08 |
| Jun 30, 2022 | 0.08 |
| Mar 31, 2022 | 0.06 |
| Dec 31, 2021 | 0.05 |
| Sep 30, 2021 | 0.05 |